Psoriasis is a chronic immune-mediated disorder which, though not life-threatening, has a great impact on the quality of life. There are multiple therapeutic options available for the treatment of psoriasis based on the severity and percentage of body surface area involved which include topicals, systemic agents, and phototherapy. It is not uncommon for patients to become resistant to therapies and treatment failures can be frustrating for the physician as well as the patient. Mycophenolate mofetil, an antimetabolite and immunosuppressant, has been found to be effective and safe for treating moderate-to-severe psoriasis in several studies. It is a good alternative for patients who fail traditional systemic treatments or who have a contraindication for their use.
LangleyR.G.B., KruegerG.C., GriffithsC.E.M.Psoriasis: epidemiology, clinical features and quality of life. Ann Rheum Dis.2005; 64: ii18–23.
2.
SterryW., BarkerJ., BoehnckeW.H.Biological therapies in the systemic management of psoriasis. International Consensus Conference. Br J Dermatol.2004; 151(suppl 69): 3–17.
3.
Grundmann-KollmannM., KortingH.C., BehrensS.Mycophenolate Mofetil: A New Therapeutic Option in the Treatment of Blistering Autoimmune Diseases. J Am Acad Dermatol.1999; 40(6 Pt 1): 957–60.
4.
MenterA., KormanN.J., ElmetsC.A.Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis with Traditional Systemic Agents. J Am Acad Dermatol.2009; 61(3): 451–85.
Fallah AraniS., Waalboer SpuijR., NijstenT., NeumannH.A., ThioB.Enteric-Coated Mycophenolate Sodium in Psoriasis Vulgaris: An Open Pilot Study. J Dermatolog Treat.2013. [Epub ahead of print].
7.
ZhouY., RosenthalD., DutzJ., HoV.Mycophenolate Mofetil (CellCept) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. J Cutan Med Surg.2003; 7(3): 193–7.
8.
SchräderP., MooserG., PeterR.U., PuhlW.Preliminary Results in the Therapy of Psoriatic Arthritis with Mycophenolate Mofetil. Z Rheumatol.2002; 61(5): 545–50.
9.
GeilenC.C., ArnoldM., OrfanosC.E.Mycophenolate Mofetil as a Systemic Antipsoriatic Agent: Positive Experience in 11 Patients. Br J Dermatol.2001; 144(3): 583–6.
10.
Grundmann-KollmanM., MooserG., SchraederP.Treatment of Chronic Plaque-Stage Psoriasis and Psoriatic Arthritis with Mycophenolate Mofetil. J Am Acad Dermatol.2000; 42(5 Pt 1): 835–7.
NaldiL.Malignancy Concerns with Psoriasis Treatments Using Phototherapy, Methotrexate, Cyclosporin, and Biologics: Facts and Controversies. Clin Dermatol.2010; 28(1): 88–92.
13.
Sandimmune (cyclosporine) package insert.
14.
BeissertS., PauserS., SticherlingM.A Comparison of Mycophenolate Mofetil with Cyclosporine for the Treatment of Chronic Plaque-Type Psoriasis. Dermatology.2009; 219(2): 126–32.
15.
PedrazJ., DaudénE., Delgado-JiménezY., García-RíoI., García-DíezA.Sequential Study on the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis with Mycophenolate Mofetil and Cyclosporin. J Eur Acad Dermatol Venereol.2006; 20(6): 702–6.
16.
DavisonS.C., Morris-JonesR., PowlesA.V., FryL.Change of Treatment from Cyclosporin to Mycophenolate Mofetil in Severe Psoriasis. Br J Dermatol.2000; 143(2): 405–7.
17.
AmeenM., SmithH.R., BarkerJ.N.Combined Mycophenolate Mofetil and Cyclosporin Therapy for Severe Recalcitrant Psoriasis. Clin Exp Dermatol.2001; 26(6): 480–3.
18.
NaldiL.Malignancy Concerns with Psoriasis Treatments Using Phototherapy, Methotrexate, Cyclosporin, and Biologics: Facts and Controversies. Clin Dermatol.2010; 28(1): 88–92.
19.
AkhyaniM., Chams-DavatchiC., HemamiM.R., FatehS.Efficacy and Safety of Mycophenolate Mofetil vs. Methotrexate for the Treatment of Chronic Plaque Psoriasis. J Eur Acad Dermatol Venereol.2010; 24(12): 1447–51.
20.
Mycophenolate Mofetil: Package Insert.
21.
NeffR.T., HurstF.P., FaltaE.M.Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation.2008; 86: 1474–1478.
22.
HalverstamC.P., LebwohlM.Nonstandard and Off-Label Therapies for Psoriasis. Clin Dermatol.2008; 26(5): 546–53.
